Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 7:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: COVID-19 Prevention Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Brief Informational Intervention for COVID-19 Misinformation Prophylaxis

NCT04557241
View directory record Official record
Conditions
COVID19 Behavioral Prophylaxis
Interventions
Brief informational infographic, Placebo control (non-behavioral infographic)
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
1,017 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Jun 7, 2026, 7:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

NCT04908722
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Ad26.COV2.S
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,609 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
18
States / cities
Little Rock, Arkansas • Anaheim, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jun 7, 2026, 7:57 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

NCT06441955
View directory record Official record
Conditions
COVID-19, Long Haul
Interventions
Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach
Drug · Diagnostic Test · Biological + 3 more
Lead sponsor
Well- Konnect Healthcare Services and Research Firm
Network
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jun 7, 2026, 7:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention

NCT05120869
View directory record Official record
Conditions
Health Personnel Attitude, Health Knowledge, Attitudes, Practice
Interventions
Tailored HPV Education and Professional Skills Intervention Group, General HPV Education and Communication Skills Control Group
Behavioral
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Las Cruces, New Mexico • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jun 7, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis

NCT05180500
View directory record Official record
Conditions
COVID-19, Pharmacokinetics, Safety
Interventions
Q-Griffithsin, Placebo
Drug
Lead sponsor
Sharon Hillier
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Jun 7, 2026, 7:57 AM EDT
Terminated Phase 4 Interventional Results available

Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization

NCT04530448
View directory record Official record
Conditions
COVID, Coronavirus, Coronavirus Infection, AKI, Acute Kidney Injury
Interventions
Sodium bicarbonate, Standard of Care
Drug · Other
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Jun 7, 2026, 7:57 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults

NCT04584710
View directory record Official record
Conditions
Covid19
Interventions
RTB101, Placebo
Drug
Lead sponsor
Restorbio Inc.
Industry
Eligibility
65 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Farmington, Connecticut • Roslindale, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Jun 7, 2026, 7:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

NCT05815498
View directory record Official record
Conditions
COVID-19
Interventions
mRNA-1283.222, mRNA-1273.222, mRNA-1283.815, mRNA-1273.815
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Years and older
Enrollment
13,553 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
161
States / cities
Huntsville, Alabama • Vestavia Hills, Alabama • Chandler, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 7, 2026, 7:57 AM EDT
Terminated Phase 2 Interventional Results available

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection

NCT04344600
View directory record Official record
Conditions
Sars-CoV-2 Infection
Interventions
Peginterferon lambda alfa-1a subcutaneous injection, Saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Jun 7, 2026, 7:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

NCT04335084
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection, COVID, Coronavirus, Coronavirus-19, Coronavirus 19
Interventions
Hydroxychloroquine, Vitamin C, Vitamin D, Zinc
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jun 7, 2026, 7:57 AM EDT
Terminated Phase 2 Interventional Results available

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

NCT05077969
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions
Famotidine, Celecoxib, Placebo
Drug
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Jun 7, 2026, 7:57 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection

NCT04372017
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Hydroxychloroquine, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Jun 7, 2026, 7:57 AM EDT
Terminated Phase 2Phase 3 Interventional

Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients

NCT04472728
View directory record Official record
Conditions
Covid-19, SARS-CoV2
Interventions
BIO101, Placebo
Drug
Lead sponsor
Biophytis
Industry
Eligibility
45 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • Irvine, California • Natchitoches, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Jun 7, 2026, 7:57 AM EDT
Completed Phase 3 Interventional Results available

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults

NCT04625972
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
50
States / cities
Guntersville, Alabama • Tempe, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Jun 7, 2026, 7:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prophylaxis and Treatment of COVID-19

NCT04844541
View directory record Official record
Conditions
COVID-19, Acute Respiratory Infection
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jun 7, 2026, 7:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Surgical Mask Use on Peak Torque, Total Work and Interset Fatigability During Isokinetic Strength Testing

NCT04706299
View directory record Official record
Conditions
Prevention of COVID-19
Interventions
Resistance Exercise
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Garfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Jun 7, 2026, 7:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

NCT05954286
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Upamostat, Placebo (PO)
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 7, 2026, 7:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers

NCT04345653
View directory record Official record
Conditions
Covid19
Interventions
Hydroxychloroquine Sulfate (HCQ)
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jun 7, 2026, 7:57 AM EDT
Completed Not applicable Interventional Results available

SAFE Workplace Intervention for People With IDD

NCT06112249
View directory record Official record
Conditions
Communicable Diseases, Prevention, Workplace Intervention
Interventions
SAFE Employment Training
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Collingswood, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jun 7, 2026, 7:57 AM EDT
Terminated Phase 3 Interventional Results available

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

NCT04498273
View directory record Official record
Conditions
COVID-19
Interventions
Apixaban 2.5 MG, Apixaban 5MG, Aspirin, Placebo
Drug
Lead sponsor
Frank C Sciurba
Other
Eligibility
40 Years to 80 Years
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
71
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Jun 7, 2026, 7:57 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC

NCT04777981
View directory record Official record
Conditions
COVID-19, SAR
Interventions
CBDRA60 supplement, Placebo
Dietary Supplement
Lead sponsor
Anewsha Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Hanover, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Jun 7, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19

NCT04592549
View directory record Official record
Conditions
SARS-CoV-2
Interventions
ADM03820, Placebo
Drug · Other
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Winston-Salem, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jun 7, 2026, 7:57 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)

NCT04363450
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, Wuhan Coronavirus, Prophylaxis, Healthcare Worker, Sars-CoV2, Hydroxychloroquine
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Lafayette, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Jun 7, 2026, 7:57 AM EDT
Completed Phase 3 Interventional Results available

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

NCT04625725
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
5,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Tempe, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Jun 7, 2026, 7:57 AM EDT